Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

51.80 +0.23 (+0.45%)

Streaming Delayed Price Updated: 9:47 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names ↗

October 11, 2024

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

Via Benzinga

FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

October 10, 2024

From Genentech

Via Business Wire

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday? ↗

October 10, 2024

Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial follows positive data from a Phase 2 study showing improved survival in patients...

Via Benzinga

Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer ↗

October 08, 2024

Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set...

Via Benzinga

Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year ↗

October 07, 2024

Scholar Rock's Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy met its primary endpoint, showing statistically significant motor function improvements and favorable outcomes compared...

Via Benzinga

2 Artificial Intelligence Stocks That Could Deliver Explosive Gains ↗

October 07, 2024

These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead.

Via The Motley Fool

Topics Artificial Intelligence

Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point? ↗

October 06, 2024

Renowned economist Justin Wolfers highlighted this significant shift on social media platform X, stating, "From the Department of Things Really Are Getting Better: The U.S. obesity rate may have...

Via Benzinga

Week In Review: Regor Sells Two CDK Inhibitors To Genentech For $850 Million ↗

October 05, 2024

Regor Pharma, a Shanghai-Boston biotech, sold global rights to Genentech for two early-stage CDK inhibitors aimed at breast cancer. Regor will receive $850 million upfront, a hefty amount for two Phase...

Via Talk Markets

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer ↗

October 04, 2024

Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.

Via Investor's Business Daily

3 Top Stocks That Could Still Rocket Higher in 2024 ↗

October 04, 2024

Upcoming Food and Drug Administration decisions could push these stocks through the roof.

Via The Motley Fool

Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential ↗

September 30, 2024

Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales. The company aims to launch 20 transformative drugs by 2030 while cutting...

Via Benzinga

Positive Phase III Results for Genentech’s Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis

September 26, 2024

From Genentech

Via Business Wire

Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points ↗

September 21, 2024

NFLX is among four stocks on the list that's actionable now.

Via Investor's Business Daily

Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows ↗

September 19, 2024

Roche's phase 3 CENTERSTONE study shows Xofluza (baloxavir marboxil) significantly reduces influenza transmission in households, marking a global first for an antiviral.

Via Benzinga

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗

September 19, 2024

Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.

Via Investor's Business Daily

Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses

September 19, 2024

From Genentech

Via Business Wire

1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc) ↗

September 17, 2024

Telemedicine once seemed like it was going to revolutionize healthcare.

Via The Motley Fool

Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections ↗

September 16, 2024

The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first twice-a-year subcutaneous injection option for both forms of the disease.

Via Benzinga

FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis

September 13, 2024

From Genentech

Via Business Wire

Time To Invest And Or Trade In Bio-Tech Stocks? ↗

September 13, 2024

Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...

Via Talk Markets

Topics ETFs

Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review ↗

September 13, 2024

The major indexes reclaimed key levels and many leaders flashed buy signals.

Via Investor's Business Daily

Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735 ↗

September 13, 2024

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right track.

Via The Motley Fool

FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

September 12, 2024

From Genentech

Via Business Wire

Why Roche Holdings Stock Withered on Wednesday ↗

September 11, 2024

The company had a dispiriting update to offer about an investigational drug.

Via The Motley Fool

Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease ↗

September 09, 2024

BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystrophy, boosting the price target from $5 to $10 due to increased confidence in...

Via Benzinga

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗

September 09, 2024

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant...

Via Benzinga

The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race ↗

August 29, 2024

The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.

Via Investor's Business Daily

Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales ↗

August 29, 2024

BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these innovative treatments face challenges in cost, scalability, and...

Via Benzinga

Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug ↗

August 27, 2024

The single-dose vials will also increase supply, the drug giant says.

Via Investor's Business Daily

Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain ↗

August 26, 2024

Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.